Melanoma, Uveal Clinical Trial
Official title:
A Phase II Clinical Trial Evaluating The Combination Of Lenvatinib Plus Pembrolizumab In Patients With Treatment Naive Metastatic Uveal Melanoma
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
This is a phase II, single arm, single institution clinical trial. Adults (ageā„18 years-old) with immune checkpoint inhibitor naïve metastatic uveal melanoma will be evaluated for eligibility. Eligible participants will be treated with the combination of Lenvatinib 20 mg daily + pembrolizumab 200 mg IV every 3 weeks for a maximum of 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04729543 -
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03467516 -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
|
Phase 2 | |
| Completed |
NCT04904120 -
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
|
Phase 1 | |
| Recruiting |
NCT05402059 -
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
|
||
| Recruiting |
NCT05655312 -
MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05315258 -
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT02874040 -
Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)
|
N/A |